Insider Selling: Axon Enterprise (NASDAQ:AXON) CFO Sells 5,000 Shares of Stock

Key Points

• Brittany Bagley, CFO of Axon Enterprise, sold 5,000 shares of stock for approximately $3.57 million, reducing her ownership by 5.07%.
• Axon Enterprise has a strong quarterly performance, reporting a 32.6% increase in revenue year-over-year, with an EPS of $2.12 exceeding estimates by $0.58.
• Institutional investors own 79.08% of Axon Enterprise, with several firms significantly increasing their stakes in the company recently.

Axon Enterprise, Inc (NASDAQ:AXON - Get Free Report) CFO Brittany Bagley sold 5,000 shares of the business's stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $713.88, for a total value of $3,569,400.00. Following the sale, the chief financial officer owned 93,592 shares of the company's stock, valued at approximately $66,813,456.96. This trade represents a 5.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Brittany Bagley also recently made the following trade(s):

• On Monday, September 15th, Brittany Bagley sold 870 shares of Axon Enterprise stock. The stock was sold at an average price of $773.25, for a total value of $672,727.50.

Axon Enterprise Price Performance

NASDAQ:AXON traded up $1.62 during trading hours on Tuesday, hitting $717.64. 608,639 shares of the stock were exchanged, compared to its average volume of 686,072. Axon Enterprise, Inc has a 52-week low of $395.37 and a 52-week high of $885.91. The firm's fifty day moving average price is $757.89 and its 200 day moving average price is $704.87. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. The company has a market cap of $56.33 billion, a P/E ratio of 177.20, a P/E/G ratio of 27.53 and a beta of 1.40.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, topping the consensus estimate of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The company had revenue of $668.54 million during the quarter, compared to analyst estimates of $641.77 million. During the same period in the previous year, the business earned $1.20 EPS. Axon Enterprise's quarterly revenue was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Hemington Wealth Management lifted its stake in Axon Enterprise by 70.8% during the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 17 shares in the last quarter. Whipplewood Advisors LLC lifted its stake in Axon Enterprise by 192.9% during the second quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 27 shares in the last quarter. Darwin Wealth Management LLC acquired a new position in Axon Enterprise during the second quarter worth $37,000. NewSquare Capital LLC lifted its stake in Axon Enterprise by 96.2% during the second quarter. NewSquare Capital LLC now owns 51 shares of the biotechnology company's stock worth $42,000 after purchasing an additional 25 shares in the last quarter. Finally, Washington Trust Advisors Inc. lifted its stake in Axon Enterprise by 44.7% during the second quarter. Washington Trust Advisors Inc. now owns 55 shares of the biotechnology company's stock worth $46,000 after purchasing an additional 17 shares in the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on AXON shares. Wolfe Research began coverage on Axon Enterprise in a research note on Monday, July 7th. They set an "outperform" rating for the company. Bank of America upped their price target on Axon Enterprise from $895.00 to $1,000.00 and gave the company a "buy" rating in a research report on Wednesday, August 6th. Needham & Company LLC restated a "buy" rating and issued a $870.00 price target on shares of Axon Enterprise in a research report on Wednesday, September 24th. Craig Hallum upgraded Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 price target for the company in a research report on Tuesday, August 5th. Finally, Raymond James Financial restated an "outperform" rating and issued a $855.00 price target (up from $645.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Fourteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Axon Enterprise currently has a consensus rating of "Moderate Buy" and a consensus price target of $841.64.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.